Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FALKON fidrisertib study in fibrodysplasia ossificans progressiva
jRCT2041220080Phase 2Completed
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Nov 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised trial of Fidrisertib in fibrodysplasia ossificans progressiva (FOP) (3 arms), sponsored by Clementia Pharmaceuticals Inc. Primary endpoints: Annualized change in heterotopic ossification volume and Incidence of adverse events and serious adverse events. Started Nov 2023; status: completed.
02
Drugs
Fidrisertib
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on jRCT2041220080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220080.